Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis
JAMA Dermatol, 2022.
Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group.
Read publication: JAMA Dermatol
Related
Associations between psoriatic arthritis and mental health among patients with psoriasis: A replicat...
Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000...
Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic ...


0 Comments